Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nascent Biotech, Inc. (NBIO)
USD0.00
+0.00 (+200.00%)
US OTC Healthcare Biotechnology
Address
623 17th Street 32960
Vero Beach, FL, US
Vero Beach, FL, US
CEO
Sean Carrick
Website
nascentbiotech.com
IPO
2009-12-03
CIK 1622057 ISIN US63108Q1013
Description
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+200.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.9K
Beta
1.76
Float Shares
99.08M
Free Float %
57.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +50.00% | 0.00% | -93.02% | -50.00% | +50.00% | -99.33% | -99.50% | -99.94% | -99.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.00
-54.6%
DCF (Levered)
0.00
+167.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-223.94
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+43.2% ★ Q3'24: +73.2% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'24: +142.1% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+31.4% Q3'24: +16.0% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.23× ★ Q3'24: -0.06× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-711.8K
OE per share TTM
-0.02
Owner's Yield
-1,377.85%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Robert D. Burke, MD | 21.27M | 16.70% | 21.27M | — | 21.27M | — | IN | United States | 2023-04-14 | ↗ |
| 2 | YA II PN, Ltd. | 12.99M | 9.99% | — | 12.99M | — | 12.99M | OO | Delaware | 2022-09-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
338.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+338,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | Karas Douglas John | Director | J-Other | A | Common stock | 50,000 | 0.10 | 5.0K | 1,821,552 | — | ↗ |
| 2024-06-30 | HOLDEN LOWELL THOMAS | Director / Officer | J-Other | A | Common stock | 96,000 | 0.09 | 8.6K | 10,005,477 | — | ↗ |
| 2024-06-30 | Carrick Sean | Director / Officer / 10% Owner | J-Other | A | Common stock | 192,000 | 0.09 | 17.3K | 23,126,007 | — | ↗ |
| 2024-03-31 | Karas Douglas John | Director | J-Other | A | Common Stock | 27,100 | 0.18 | 5.0K | 1,771,552 | — | ↗ |
| 2024-03-31 | HOLDEN LOWELL THOMAS | Director / Officer | J-Other | A | Common Stock | 112,500 | 0.18 | 20.8K | 9,909,477 | — | ↗ |
| 2024-03-31 | Carrick Sean | Director / Officer / 10% Owner | J-Other | A | Common Stock | 225,000 | 0.18 | 41.5K | 22,934,007 | — | ↗ |
| 2023-12-29 | Karas Douglas John | Director | J-Other | A | Common Stock | 28,935 | 0.18 | 5.2K | 1,744,452 | — | ↗ |
| 2023-12-29 | HOLDEN LOWELL THOMAS | Director / Officer | J-Other | A | Common Stock | 119,650 | 0.17 | 20.3K | 9,796,977 | — | ↗ |
| 2023-12-29 | Carrick Sean | Director / Officer / 10% Owner | J-Other | A | Common Stock | 239,300 | 0.17 | 40.7K | 22,709,007 | — | ↗ |
| 2023-09-29 | Karas Douglas John | Director | J-Other | A | Common Stock | 39,750 | 0.13 | 5.0K | 1,715,517 | — | ↗ |
| 2023-09-29 | HOLDEN LOWELL THOMAS | Director / Officer | J-Other | A | Common Stock | 1,386,300 | 0.13 | 173.3K | 9,677,327 | — | ↗ |
| 2023-09-29 | Carrick Sean | Director / Officer / 10% Owner | J-Other | A | Common Stock | 2,772,600 | 0.13 | 346.6K | 22,469,707 | — | ↗ |
| 2023-06-29 | HOLDEN LOWELL THOMAS | Director / Officer | G-Gift | D | Common Stock | 700,000 | 0.05 | 34.3K | 8,291,027 | — | ↗ |
| 2023-06-29 | Carrick Sean | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 960,000 | 0.05 | 48.0K | 19,697,107 | — | ↗ |
| 2023-06-07 | HOLDEN LOWELL THOMAS | Director / Officer | P-Purchase | A | Common stock | 130,000 | 0.04 | 5.2K | 8,409,277 | — | ↗ |
| 2023-03-31 | Karas Douglas John | Director | J-Other | A | Common Stock | 89,285 | 0.06 | 5.4K | 1,575,767 | — | ↗ |
| 2023-03-31 | HOLDEN LOWELL THOMAS | Director / Officer | J-Other | A | Common stock | 581,000 | 0.06 | 34.9K | 8,279,277 | — | ↗ |
| 2023-03-31 | Carrick Sean | Director / Officer / 10% Owner | J-Other | A | Common Stock | 1,167,000 | 0.06 | 70.0K | 19,233,607 | — | ↗ |
| 2023-02-09 | HOLDEN LOWELL THOMAS | — | G-Gift | D | Common stock | 700,000 | 0.12 | 84.0K | 7,798,277 | — | ↗ |
| 2023-01-27 | HOLDEN LOWELL THOMAS | — | P-Purchase | A | Common Stock | 20,000 | 0.14 | 2.8K | 8,418,277 | — | ↗ |
| 2022-12-30 | Karas Douglas John | Director | J-Other | A | Common Stock | 25,000 | 0.20 | 5.0K | 1,486,482 | — | ↗ |
| 2022-12-30 | HOLDEN LOWELL THOMAS | Director | A-Award | A | Common Stock | 231,000 | 0.20 | 46.2K | 8,398,277 | — | ↗ |
| 2022-12-30 | Carrick Sean | Director | J-Other | A | Common Stock | 462,000 | 0.20 | 92.4K | 18,071,607 | — | ↗ |
| 2022-07-21 | HOLDEN LOWELL THOMAS | Director | S-Sale | D | Common Stock | 5,000 | 0.26 | 1.3K | 8,112,277 | — | ↗ |
| 2022-04-14 | HOLDEN LOWELL THOMAS | Director | G-Gift | D | Common stock | 700,000 | 0.08 | 56.0K | 8,283,077 | — | ↗ |
| 2022-03-31 | Carrick Sean | Director / Officer / 10% Owner | J-Other | A | Common Stock | 430,000 | 0.06 | 24.1K | 17,451,131 | — | ↗ |
| 2022-03-09 | Karas Douglas John | Director | J-Other | A | Common Stock | 300,000 | 0.05 | 15.0K | 1,427,853 | — | ↗ |
| 2022-03-09 | HOLDEN LOWELL THOMAS | Director | J-Other | A | Common Stock | 215,000 | 0.06 | 12.0K | 8,983,077 | — | ↗ |
| 2022-03-09 | Carrick Sean | Director | J-Other | A | Common Stock | 1,000,000 | 0.05 | 50.0K | 17,021,131 | — | ↗ |
| 2022-01-07 | HOLDEN LOWELL THOMAS | — | G-Gift | D | Common Stock | 1,700,000 | 0.05 | 85.0K | 7,141,777 | — | ↗ |
| 2021-06-30 | Karas Douglas John | — | J-Other | A | Common Stock | 83,334 | 0.11 | 8.8K | 1,127,854 | — | ↗ |
| 2021-06-30 | HOLDEN LOWELL THOMAS | — | J-Other | D | Common Stock | 700,000 | 0.11 | 73.5K | 8,668,077 | — | ↗ |
| 2021-06-30 | Carrick Sean | — | J-Other | A | Common Stock | 347,400 | 0.11 | 36.5K | 16,021,131 | — | ↗ |
| 2021-04-15 | HOLDEN LOWELL THOMAS | — | G-Gift | D | Common Stock | 1,700,000 | 0.05 | 85.0K | 8,668,077 | — | ↗ |
| 2021-04-09 | Karas Douglas John | — | J-Other | A | Common Stock | 307,010 | 0.08 | 23.3K | 1,044,520 | — | ↗ |
| 2021-03-31 | Karas Douglas John | — | J-Other | A | Common Stock | 83,334 | 0.07 | 5.8K | 773,224 | — | ↗ |
| 2021-03-31 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 810,000 | 0.06 | 49.4K | 10,368,077 | — | ↗ |
| 2021-03-31 | Carrick Sean | — | J-Other | A | Common Stock | 1,620,000 | 0.06 | 98.8K | 15,673,731 | — | ↗ |
| 2021-03-26 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 1,000,000 | 0.06 | 60.0K | 9,558,077 | — | ↗ |
| 2021-03-26 | Carrick Sean | — | J-Other | A | Common Stock | 1,250,000 | 0.06 | 75.0K | 14,048,731 | — | ↗ |
| 2020-12-31 | Karas Douglas John | — | J-Other | A | Common Stock | 108,460 | 0.05 | 5.0K | 689,890 | — | ↗ |
| 2020-12-31 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 1,442,000 | 0.05 | 66.5K | 8,558,077 | — | ↗ |
| 2020-12-31 | Carrick Sean | — | J-Other | A | Common Stock | 2,884,000 | 0.05 | 133.0K | 12,803,731 | — | ↗ |
| 2020-11-20 | Karas Douglas John | — | J-Other | A | Common Stock | 350,000 | 0.05 | 17.5K | 581,490 | — | ↗ |
| 2020-09-30 | Karas Douglas John | — | J-Other | A | Common Stock | 71,430 | 0.07 | 5.0K | 231,490 | — | ↗ |
| 2020-09-30 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 127,970 | 0.07 | 9.0K | 7,116,077 | — | ↗ |
| 2020-09-30 | Carrick Sean | — | J-Other | A | Common Stock | 218,715 | 0.10 | 21.9K | 9,919,731 | — | ↗ |
| 2020-06-29 | Price Brandon | — | J-Other | A | Common Stock | 534,000 | 0.10 | 53.4K | 7,002,328 | — | ↗ |
| 2020-06-29 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 534,000 | 0.10 | 53.4K | 6,988,107 | — | ↗ |
| 2020-06-29 | Carrick Sean | — | J-Other | A | Common Stock | 889,000 | 0.10 | 88.9K | 9,701,016 | — | ↗ |
| 2020-06-24 | Price Brandon | — | J-Other | A | Common Stock (conversion of debt to equity) | 2,821,830 | 0.10 | 282.2K | 6,468,328 | — | ↗ |
| 2020-06-24 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock (conversion of debt to equity) | 2,901,890 | 0.10 | 290.2K | 6,454,107 | — | ↗ |
| 2020-06-24 | Carrick Sean | — | J-Other | A | Common Stock (Conversion of debt to equity) | 6,155,000 | 0.10 | 615.5K | 8,812,016 | — | ↗ |
| 2020-05-11 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 1,000,000 | 0.10 | 100.0K | 3,562,217 | — | ↗ |
| 2020-03-27 | Price Brandon | — | J-Other | A | Common stock | 265,160 | 0.13 | 34.5K | 2,694,117 | — | ↗ |
| 2020-03-27 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common stock | 265,160 | 0.13 | 34.5K | 2,562,217 | — | ↗ |
| 2020-03-27 | Carrick Sean | — | J-Other | A | Common stock | 441,930 | 0.13 | 57.5K | 2,657,016 | — | ↗ |
| 2019-12-30 | Price Brandon | — | J-Other | A | Common Stock | 56,700 | 0.10 | 5.7K | 2,428,957 | — | ↗ |
| 2019-12-30 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 56,700 | 0.10 | 5.7K | 2,287,057 | — | ↗ |
| 2019-12-30 | Glassy Mark | — | J-Other | A | Common Stock (conversion of debt to equity) | 90,000 | 0.10 | 9.0K | 4,276,500 | — | ↗ |
| 2019-12-30 | Carrick Sean | — | J-Other | A | Common Stock | 94,500 | 0.10 | 9.5K | 2,215,086 | — | ↗ |
| 2019-12-26 | HOLDEN LOWELL THOMAS | — | P-Purchase | A | Common Stock | 5,000 | 0.17 | 825.00 | 2,292,057 | — | ↗ |
| 2019-10-03 | HOLDEN LOWELL THOMAS | — | P-Purchase | A | Common Stock | 10,000 | 0.14 | 1.4K | 1,410,357 | — | ↗ |
| 2019-09-30 | Price Brandon | — | J-Other | A | Common Stock | 7,500 | 0.13 | 945.00 | 1,672,257 | — | ↗ |
| 2019-09-30 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 7,500 | 0.13 | 960.00 | 1,400,357 | — | ↗ |
| 2019-09-30 | Carrick Sean | — | J-Other | A | Common Stock | 12,500 | 0.13 | 1.6K | 1,910,586 | — | ↗ |
| 2019-06-25 | Price Brandon | — | J-Other | A | Common Stock | 23,965 | 0.19 | 4.5K | 1,664,757 | — | ↗ |
| 2019-06-25 | Karas Douglas John | — | J-Other | A | Common Stock | 50,000 | 0.19 | 9.3K | 110,000 | — | ↗ |
| 2019-06-25 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 23,965 | 0.19 | 4.5K | 1,392,857 | — | ↗ |
| 2019-06-25 | Carrick Sean | — | J-Other | A | Common Stock | 39,942 | 0.19 | 7.4K | 1,898,086 | — | ↗ |
| 2019-06-04 | Price Brandon | — | A-Award | A | Common Stock | 368,218 | 0.15 | 56.7K | 1,640,792 | — | ↗ |
| 2019-06-04 | HOLDEN LOWELL THOMAS | — | A-Award | A | Common Stock | 271,318 | 0.15 | 41.8K | 1,368,892 | — | ↗ |
| 2019-03-26 | Price Brandon | — | J-Other | A | Common Stock | 63,200 | 0.15 | 9.5K | 1,272,574 | — | ↗ |
| 2019-03-25 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 63,200 | 0.15 | 9.5K | 1,097,574 | — | ↗ |
| 2019-03-25 | Carrick Sean | — | J-Other | A | Common Stock | 100,637 | 0.15 | 15.1K | 1,858,144 | — | ↗ |
| 2018-12-31 | Price Brandon | — | J-Other | A | Common Stock | 18,202 | 0.17 | 3.1K | 1,209,374 | — | ↗ |
| 2018-12-31 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 18,202 | 0.17 | 3.1K | 1,034,374 | — | ↗ |
| 2018-12-31 | Carrick Sean | — | J-Other | A | Common Stock | 30,337 | 0.17 | 5.2K | 1,757,507 | — | ↗ |
| 2018-09-28 | Price Brandon | — | J-Other | A | Common Stock | 59,687 | 0.19 | 11.3K | 1,191,172 | — | ↗ |
| 2018-09-28 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 59,683 | 0.19 | 11.3K | 1,016,172 | — | ↗ |
| 2018-09-28 | Carrick Sean | — | J-Other | A | Common Stock | 99,478 | 0.19 | 18.9K | 1,727,170 | — | ↗ |
| 2018-06-28 | Price Brandon | — | J-Other | A | Common Stock | 23,942 | 0.50 | 12.0K | 1,131,485 | — | ↗ |
| 2018-06-28 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 23,942 | 0.50 | 12.0K | 956,485 | — | ↗ |
| 2018-06-28 | Carrick Sean | — | J-Other | A | Common Stock | 39,904 | 0.50 | 20.0K | 1,627,692 | — | ↗ |
| 2018-03-30 | Price Brandon | — | J-Other | A | Common Stock | 15,210 | 0.25 | 3.8K | 1,107,543 | — | ↗ |
| 2018-03-30 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 15,210 | 0.25 | 3.8K | 932,547 | — | ↗ |
| 2018-03-30 | Carrick Sean | — | J-Other | A | Common Stock | 25,350 | 0.25 | 6.3K | 1,587,788 | — | ↗ |
| 2017-12-29 | Price Brandon | — | J-Other | A | Common Stock | 7,601 | 0.18 | 1.4K | 1,092,333 | — | ↗ |
| 2017-12-29 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 7,601 | 0.18 | 1.4K | 917,337 | — | ↗ |
| 2017-12-29 | Carrick Sean | — | J-Other | A | Common Stock | 12,685 | 0.18 | 2.3K | 1,562,438 | — | ↗ |
| 2017-10-09 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 10,000 | 0.25 | 2.5K | 919,732 | — | ↗ |
| 2017-09-28 | Price Brandon | — | J-Other | A | Common Stock | 98,354 | 0.25 | 24.4K | 1,084,732 | — | ↗ |
| 2017-09-28 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 98,354 | 0.25 | 24.4K | 909,732 | — | ↗ |
| 2017-09-28 | Carrick Sean | — | J-Other | A | Common Stock | 163,923 | 0.25 | 40.7K | 1,549,753 | — | ↗ |
| 2017-09-27 | Price Brandon | — | J-Other | A | Common Stock | 98,354 | 0.25 | 24.6K | 1,084,732 | — | ↗ |
| 2017-09-27 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 98,354 | 0.25 | 24.6K | 909,736 | — | ↗ |
| 2017-09-27 | Carrick Sean | — | J-Other | A | Common Stock | 163,923 | 0.25 | 41.0K | 1,549,753 | — | ↗ |
| 2017-08-14 | Karas Douglas John | — | J-Other | A | Common Stock | 50,000 | 0.22 | 11.0K | 60,000 | — | ↗ |
| 2017-06-29 | Price Brandon | — | J-Other | A | Common Stock | 20,678 | 0.30 | 6.2K | 986,378 | — | ↗ |
| 2017-06-29 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 20,678 | 0.30 | 6.2K | 811,378 | — | ↗ |
| 2017-06-29 | Carrick Sean | — | J-Other | A | Common Stock | 34,464 | 0.30 | 10.3K | 1,385,830 | — | ↗ |
| 2017-06-26 | Price Brandon | — | J-Other | A | Common Stock | 20,678 | 0.30 | 6.2K | 986,378 | — | ↗ |
| 2017-06-26 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 20,678 | 0.30 | 6.2K | 811,382 | — | ↗ |
| 2017-06-26 | Carrick Sean | — | J-Other | A | Common Stock | 34,464 | 0.30 | 10.3K | 1,385,830 | — | ↗ |
| 2017-03-28 | Price Brandon | — | J-Other | A | Common Stock | 38,213 | 0.38 | 14.5K | 965,700 | — | ↗ |
| 2017-03-28 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 38,213 | 0.38 | 14.5K | 790,700 | — | ↗ |
| 2017-03-28 | Carrick Sean | — | J-Other | A | Common Stock | 63,688 | 0.38 | 24.2K | 1,351,366 | — | ↗ |
| 2016-12-30 | Price Brandon | — | J-Other | A | Common Stock | 7,800 | 0.35 | 2.7K | 927,487 | — | ↗ |
| 2016-12-30 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 7,800 | 0.35 | 2.7K | 752,487 | — | ↗ |
| 2016-12-30 | Carrick Sean | — | J-Other | A | Common Stock | 13,000 | 0.35 | 4.6K | 1,287,678 | — | ↗ |
| 2015-10-08 | Carrick Sean | — | P-Purchase | A | Common Stock | 1,500 | 0.20 | 300.00 | 1,227,601 | — | ↗ |
| 2015-09-04 | Price Brandon | — | J-Other | A | Common Stock | 617,346 | 1.45 | 895.2K | 892,346 | — | ↗ |
| 2015-09-04 | HOLDEN LOWELL THOMAS | — | J-Other | A | Common Stock | 617,346 | 1.45 | 895.2K | 717,346 | — | ↗ |
| 2015-09-04 | Carrick Sean | — | J-Other | A | Common Stock | 1,028,901 | 1.45 | 1.49M | 1,226,101 | — | ↗ |
| 2015-04-03 | Karas Douglas John | — | P-Purchase | A | Common Stock | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2014-07-15 | HOLDEN LOWELL THOMAS | — | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2014-07-15 | Carrick Sean | — | — | D | Common Stock | 0 | 0.00 | — | 200,200 | — | ↗ |
| 2014-07-14 | Price Brandon | — | — | D | Common Stock | 0 | 0.00 | — | 275,000 | — | ↗ |
| 2014-03-14 | Glassy Mark | — | — | D | Common Stock | 0 | 0.00 | — | 4,186,500 | — | ↗ |
Executive team
Top executives
Shares Outstanding
172.22M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean Carrick | President, Chief Executive Officer, Secretary & Director | 252.0K | male |
| Lowell Holden | Chief Financial Officer, Chief Accounting Officer & Director | 180.0K | male |
| Mark C. Glassy | Founder | 43.0K | — |
| Navpaul Singh | Chief Medical Consultant | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
